AplaGen is committed to significant improvements for patients with dysfunctional bone marrow. Priority is given to peptides which mimic the action of important cytokines, especially erythropoietin (EPO) and thrombopoietin (TPO) .
Prognosis and quality of life of many patients depend on proper bone marrow function with appropriate production of red blood cells (EPO) and blood platelets (TPO).
Recombinant thrombopoietin is immunogenic and clinically useless. For recombinant EPOs there are restrictions of use in place. Priming a new class of cost-effectiv agents and combining this with an innovative clinical strategy, AplaGen is dedicated to overcome these limitations and to significantly improve prognosis and quality of life of patients with dysfunctional bone marrow, especially oncologic patients.